Cargando…
Body fat composition as predictive factor for treatment response in patients with newly diagnosed multiple myeloma – subgroup analysis of the prospective GMMG MM5 trial
INTRODUCTION/BACKGROUND: Obesity is a well-known risk factor for malignant tumors and increased body mass index (BMI) is correlated to the risk of developing multiple myeloma (MM). The correlation of body fat composition with disease activity, adverse events and treatment response of MM patients has...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620270/ https://www.ncbi.nlm.nih.gov/pubmed/28978130 http://dx.doi.org/10.18632/oncotarget.19536 |
_version_ | 1783267552134168576 |
---|---|
author | GroΔ, Jonathan P. Nattenmüller, Johanna Hemmer, Stefan Tichy, Diana Krzykalla, Julia Goldschmidt, Hartmut Bertsch, Uta Delorme, Stefan Kauczor, Hans-Ulrich Hillengass, Jens Merz, Maximilian |
author_facet | GroΔ, Jonathan P. Nattenmüller, Johanna Hemmer, Stefan Tichy, Diana Krzykalla, Julia Goldschmidt, Hartmut Bertsch, Uta Delorme, Stefan Kauczor, Hans-Ulrich Hillengass, Jens Merz, Maximilian |
author_sort | GroΔ, Jonathan P. |
collection | PubMed |
description | INTRODUCTION/BACKGROUND: Obesity is a well-known risk factor for malignant tumors and increased body mass index (BMI) is correlated to the risk of developing multiple myeloma (MM). The correlation of body fat composition with disease activity, adverse events and treatment response of MM patients has not been investigated yet. PATIENTS AND METHODS: A subgroup of 108 patients from a single institution enrolled in the prospective GMMG-MM5 trial, who received a whole-body low-dose computed tomography (WBLDCT) before induction therapy, were included in this study. Body fat composition was measured in WBLDCT for each patient, divided in the compartments abdomen, pelvis, thigh and further categorized in subcutaneous (SAT) and visceral adipose tissue (VAT). The correlation of these parameters with disease activity (M protein, plasma cell count, LDH, CRAB-criteria), adverse cytogenetics, adverse events and treatment response were evaluated. RESULTS: Significant reciprocal correlation was found between adverse cytogenetics and VAT of the abdomen and pelvis, respectively (gain 1q21: p=0.009 and p=0.021; t(4;14): p=0.038 and p=0.042). No correlation of VAT or SAT with adverse events was observed. Significant reciprocal correlation was observed between abdominal (p=0.03) and pelvic (p=0.035) VAT and treatment response. Abdominal VAT remains significant (p=0.034) independently of revised ISS stage and treatment. The BMI did not show a significant correlation with treatment response or investigated cytogenetics. CONCLUSION: Based on the clinically relevant difference in treatment outcome depending on VAT and SAT, excessive body fat of abdomen and pelvis might be a predictive factor for poor treatment response. Further influences in this context should be considered as well, e.g. chemotherapy dosing and body fat metabolism. Further studies are necessary to investigate this hypothesis. |
format | Online Article Text |
id | pubmed-5620270 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-56202702017-10-03 Body fat composition as predictive factor for treatment response in patients with newly diagnosed multiple myeloma – subgroup analysis of the prospective GMMG MM5 trial GroΔ, Jonathan P. Nattenmüller, Johanna Hemmer, Stefan Tichy, Diana Krzykalla, Julia Goldschmidt, Hartmut Bertsch, Uta Delorme, Stefan Kauczor, Hans-Ulrich Hillengass, Jens Merz, Maximilian Oncotarget Research Paper INTRODUCTION/BACKGROUND: Obesity is a well-known risk factor for malignant tumors and increased body mass index (BMI) is correlated to the risk of developing multiple myeloma (MM). The correlation of body fat composition with disease activity, adverse events and treatment response of MM patients has not been investigated yet. PATIENTS AND METHODS: A subgroup of 108 patients from a single institution enrolled in the prospective GMMG-MM5 trial, who received a whole-body low-dose computed tomography (WBLDCT) before induction therapy, were included in this study. Body fat composition was measured in WBLDCT for each patient, divided in the compartments abdomen, pelvis, thigh and further categorized in subcutaneous (SAT) and visceral adipose tissue (VAT). The correlation of these parameters with disease activity (M protein, plasma cell count, LDH, CRAB-criteria), adverse cytogenetics, adverse events and treatment response were evaluated. RESULTS: Significant reciprocal correlation was found between adverse cytogenetics and VAT of the abdomen and pelvis, respectively (gain 1q21: p=0.009 and p=0.021; t(4;14): p=0.038 and p=0.042). No correlation of VAT or SAT with adverse events was observed. Significant reciprocal correlation was observed between abdominal (p=0.03) and pelvic (p=0.035) VAT and treatment response. Abdominal VAT remains significant (p=0.034) independently of revised ISS stage and treatment. The BMI did not show a significant correlation with treatment response or investigated cytogenetics. CONCLUSION: Based on the clinically relevant difference in treatment outcome depending on VAT and SAT, excessive body fat of abdomen and pelvis might be a predictive factor for poor treatment response. Further influences in this context should be considered as well, e.g. chemotherapy dosing and body fat metabolism. Further studies are necessary to investigate this hypothesis. Impact Journals LLC 2017-07-25 /pmc/articles/PMC5620270/ /pubmed/28978130 http://dx.doi.org/10.18632/oncotarget.19536 Text en Copyright: © 2017 GroΔ et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Research Paper GroΔ, Jonathan P. Nattenmüller, Johanna Hemmer, Stefan Tichy, Diana Krzykalla, Julia Goldschmidt, Hartmut Bertsch, Uta Delorme, Stefan Kauczor, Hans-Ulrich Hillengass, Jens Merz, Maximilian Body fat composition as predictive factor for treatment response in patients with newly diagnosed multiple myeloma – subgroup analysis of the prospective GMMG MM5 trial |
title | Body fat composition as predictive factor for treatment response in patients with newly diagnosed multiple myeloma – subgroup analysis of the prospective GMMG MM5 trial |
title_full | Body fat composition as predictive factor for treatment response in patients with newly diagnosed multiple myeloma – subgroup analysis of the prospective GMMG MM5 trial |
title_fullStr | Body fat composition as predictive factor for treatment response in patients with newly diagnosed multiple myeloma – subgroup analysis of the prospective GMMG MM5 trial |
title_full_unstemmed | Body fat composition as predictive factor for treatment response in patients with newly diagnosed multiple myeloma – subgroup analysis of the prospective GMMG MM5 trial |
title_short | Body fat composition as predictive factor for treatment response in patients with newly diagnosed multiple myeloma – subgroup analysis of the prospective GMMG MM5 trial |
title_sort | body fat composition as predictive factor for treatment response in patients with newly diagnosed multiple myeloma – subgroup analysis of the prospective gmmg mm5 trial |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620270/ https://www.ncbi.nlm.nih.gov/pubmed/28978130 http://dx.doi.org/10.18632/oncotarget.19536 |
work_keys_str_mv | AT grodjonathanp bodyfatcompositionaspredictivefactorfortreatmentresponseinpatientswithnewlydiagnosedmultiplemyelomasubgroupanalysisoftheprospectivegmmgmm5trial AT nattenmullerjohanna bodyfatcompositionaspredictivefactorfortreatmentresponseinpatientswithnewlydiagnosedmultiplemyelomasubgroupanalysisoftheprospectivegmmgmm5trial AT hemmerstefan bodyfatcompositionaspredictivefactorfortreatmentresponseinpatientswithnewlydiagnosedmultiplemyelomasubgroupanalysisoftheprospectivegmmgmm5trial AT tichydiana bodyfatcompositionaspredictivefactorfortreatmentresponseinpatientswithnewlydiagnosedmultiplemyelomasubgroupanalysisoftheprospectivegmmgmm5trial AT krzykallajulia bodyfatcompositionaspredictivefactorfortreatmentresponseinpatientswithnewlydiagnosedmultiplemyelomasubgroupanalysisoftheprospectivegmmgmm5trial AT goldschmidthartmut bodyfatcompositionaspredictivefactorfortreatmentresponseinpatientswithnewlydiagnosedmultiplemyelomasubgroupanalysisoftheprospectivegmmgmm5trial AT bertschuta bodyfatcompositionaspredictivefactorfortreatmentresponseinpatientswithnewlydiagnosedmultiplemyelomasubgroupanalysisoftheprospectivegmmgmm5trial AT delormestefan bodyfatcompositionaspredictivefactorfortreatmentresponseinpatientswithnewlydiagnosedmultiplemyelomasubgroupanalysisoftheprospectivegmmgmm5trial AT kauczorhansulrich bodyfatcompositionaspredictivefactorfortreatmentresponseinpatientswithnewlydiagnosedmultiplemyelomasubgroupanalysisoftheprospectivegmmgmm5trial AT hillengassjens bodyfatcompositionaspredictivefactorfortreatmentresponseinpatientswithnewlydiagnosedmultiplemyelomasubgroupanalysisoftheprospectivegmmgmm5trial AT merzmaximilian bodyfatcompositionaspredictivefactorfortreatmentresponseinpatientswithnewlydiagnosedmultiplemyelomasubgroupanalysisoftheprospectivegmmgmm5trial |